pioglitazone has been researched along with Mouth Neoplasms in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Mouth Neoplasms: Tumors or cancer of the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral squamous cell carcinomas (OSCC) were induced in male F344 rats by 4-nitroquinoline-1-oxide (NQO; 20 ppm in the drinking water for 10 weeks)." | 1.42 | Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ. ( Horn, TL; Johnson, WD; Lubet, RA; McCormick, DL; Peng, X; Steele, VE, 2015) |
| "Pioglitazone has a null association with oral cancer after adjustment for potential confounders." | 1.40 | Pioglitazone and oral cancer risk in patients with type 2 diabetes. ( Tseng, CH, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosas, RR | 1 |
| Nachbor, KM | 1 |
| Handley, N | 1 |
| Mathison, G | 1 |
| Wuertz, BR | 1 |
| Ba'th, F | 1 |
| Ondrey, FG | 1 |
| Tseng, CH | 1 |
| McCormick, DL | 1 |
| Horn, TL | 1 |
| Johnson, WD | 1 |
| Peng, X | 1 |
| Lubet, RA | 1 |
| Steele, VE | 1 |
| Nakashiro, K | 1 |
| Begum, NM | 1 |
| Uchida, D | 1 |
| Kawamata, H | 1 |
| Shintani, S | 1 |
| Sato, M | 1 |
| Hamakawa, H | 1 |
4 other studies available for pioglitazone and Mouth Neoplasms
| Article | Year |
|---|---|
Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention.
Topics: Bexarotene; Chemoprevention; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Pioglitazone; United | 2022 |
Pioglitazone and oral cancer risk in patients with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle | 2014 |
Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.
Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Male; Mouth Neop | 2015 |
Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Chromans; DNA Mutational Analysis; Humans; Mouth Neoplas | 2003 |